Lifestyle changes and remedies such as topical estrogen can be of assistance to cancer survivors dealing with hormone deficiencies, as one expert tells CURE.
Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrine .
FDA Approves First Once-Weekly Growth Hormone for Children medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth .
Lumos Pharma, Inc.April 14, 2021 GMT
AUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it will host a key opinion leader (KOL) webinar on LUM-201 on Tuesday, April 27, 2021, at 10:30am ET. LUM-201 is the Company’s orally administered therapeutic candidate for the treatment of pediatric growth hormone deficiency (PGHD).
The event will feature presentations by KOLs in the field of pediatric endocrinology, Bradley S. Miller, M.D., Ph.D., University of Minnesota, and Fernando Cassorla, M.D., University of Chile, who will discuss the currently available treatments and unmet medical needs in PGHD. Drs. Miller and Cassorla will be available to answer questi
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET
April 14, 2021 16:05 ET | Source: Lumos Pharma, Inc. Lumos Pharma, Inc. Austin, Texas, UNITED STATES
AUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it will host a key opinion leader (KOL) webinar on LUM-201 on Tuesday, April 27, 2021, at 10:30am ET. LUM-201 is the Company’s orally administered therapeutic candidate for the treatment of pediatric growth hormone deficiency (PGHD).